The U.S. Food and Drug Administration’s Office of the Chief Medical Officer (OCMO) has released a public agenda outlining guidance documents it plans to publish from 2025 through 2027, according to material posted on FDA.gov. The agenda lists guidance documents the office intends to issue in calendar year 2025, as well as guidance it is developing for release in 2026 and 2027, and invites public review and input.
While the agenda itself is a planning document rather than a binding rule, it offers an early look at how the OCMO expects to shape its written recommendations to health care providers, patients, and regulated entities over the next three years.
What the OCMO Guidance Agenda Does
The FDA describes the OCMO Guidance Agenda as a set of planned guidance documents that the office “intends to publish” in specified calendar years, based on the information available when the agenda is compiled. The agenda is organized by year, with one list for 2025 and another for guidance documents under development for 2026–2027.
Guidance documents are FDA’s formal written recommendations on how the agency interprets and applies existing laws and regulations. They do not themselves create new legal requirements, but they can strongly influence how treatments are developed, evaluated, and used in practice.
According to the agenda posted on FDA.gov, the OCMO is using this planning tool to:
- Share, in one place, the guidance topics it expects to prioritize in the near term
- Signal which guidance documents are already in development for later years
- Invite public review and input on the planned topics before the guidance is finalized
The FDA notes in its materials that inclusion of a topic on the agenda does not guarantee a specific publication date. Instead, the agenda is presented as an intention and planning aid, subject to change as scientific, clinical, or public health needs evolve.
Who Is Involved and How the Process Works
The agenda is produced by the Office of the Chief Medical Officer, a senior office within the FDA that focuses on medical and scientific oversight across the agency’s work. The OCMO coordinates with other FDA centers and offices when developing guidance, but the agenda itself is issued under the OCMO’s name.
In its online materials, the FDA explains that guidance development typically involves:
- Identifying a need for clarification on a scientific, clinical, or regulatory issue
- Drafting guidance text that reflects the agency’s current thinking
- Seeking input from relevant FDA centers and subject-matter experts
- Providing opportunities for public comment, often through draft guidance publication
The OCMO Guidance Agenda fits into this process at the planning stage. By listing guidance topics ahead of time, the office is signaling where it expects to focus its efforts and giving outside stakeholders an early chance to prepare comments or feedback.
The FDA states on its website that it welcomes public engagement on guidance topics. For many guidance documents, the agency follows a process in which a draft is issued for public comment before a final version is published. The agenda does not replace that step, but it does precede it by indicating which topics are likely to move into drafting and publication.
Why the Agenda Matters for Patients and Providers
The agenda itself does not change how medicines are prescribed, how clinical trials are run, or how products are regulated. However, the FDA’s guidance documents can influence those areas once they are issued, and the agenda offers an early view of where that influence may be felt.
Because the OCMO sits at the intersection of clinical practice and regulatory science within the FDA, the guidance topics it prioritizes can affect:
- How quickly clinicians receive FDA’s written recommendations on emerging medical issues
- The clarity of FDA expectations for health care organizations and researchers
- The speed with which providers and patients can adjust to new scientific evidence as it is reflected in FDA guidance
The FDA’s own description on FDA.gov emphasizes that guidance is meant to communicate the agency’s “current thinking” on a topic. When new guidance is released, it can help standardize how health systems and clinicians interpret FDA regulations and scientific findings.
By publishing a multi-year agenda, the OCMO is giving hospitals, professional societies, patient groups, and industry organizations a preview of where new or updated guidance may appear. Those groups can use the agenda to plan their own review, comment, and education efforts once draft or final guidance becomes available.
Limits of What Is Known So Far
The current public information comes directly from FDA.gov, which presents the OCMO Guidance Agenda and describes its purpose. Independent corroboration of the agenda’s details beyond the FDA’s own publication is limited at this stage and should be monitored as additional reporting or analysis becomes available.
The FDA notes that the agenda is not exhaustive and may change. Guidance topics can be added, removed, or reprioritized as circumstances shift, and the presence of a topic on the list does not guarantee a specific timeline for publication.
For now, the agenda functions primarily as a planning and transparency tool. It shows what the OCMO intends to work on in terms of guidance documents for 2025 and what is already in development for 2026–2027, based on the information the office has chosen to share on its website.
What Readers Should Watch Next
The most immediate next steps will come as the OCMO begins publishing the guidance documents listed for calendar year 2025 and continues work on those planned for 2026–2027. As those individual guidance documents are released—often first in draft form—patients, clinicians, and organizations will have more concrete text to review and respond to.
For readers, the key developments to watch on FDA.gov are:
- Publication of draft guidance documents that correspond to topics on the OCMO Guidance Agenda
- Opening of public comment periods on those drafts
- Release of final guidance documents after the comment and revision process
Each of those steps will provide more specific information about how the FDA’s current thinking is evolving and what that may mean for treatment access, regulatory expectations, and how quickly providers and patients respond to new clinical guidance.
At this stage, the OCMO Guidance Agenda is a roadmap rather than a destination. It signals where the FDA’s Chief Medical Office expects to focus its guidance work through 2027 and invites the public to pay attention—and, when the opportunity arises, to weigh in.
